NORTHERN TRUST CORP - KALVISTA PHARMACEUTICALS INC ownership

KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of KALVISTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,650,350
+12.6%
275,218
+5.2%
0.00%
Q2 2023$2,354,544
+26.9%
261,616
+10.8%
0.00%
Q1 2023$1,855,848
+13.5%
236,113
-2.4%
0.00%
Q4 2022$1,635,670
-53.9%
241,963
-1.1%
0.00%
-100.0%
Q3 2022$3,550,000
+47.7%
244,696
+0.2%
0.00%0.0%
Q2 2022$2,404,000
-34.1%
244,218
-1.4%
0.00%0.0%
Q1 2022$3,650,000
+8.2%
247,676
-2.8%
0.00%0.0%
Q4 2021$3,372,000
-17.3%
254,909
+9.1%
0.00%0.0%
Q3 2021$4,079,000
-29.6%
233,740
-3.3%
0.00%0.0%
Q2 2021$5,794,000
-1.4%
241,833
+5.8%
0.00%0.0%
Q1 2021$5,875,000
+35.0%
228,670
-0.3%
0.00%0.0%
Q4 2020$4,353,000
+44.7%
229,244
-4.0%
0.00%0.0%
Q3 2020$3,008,000
+2.7%
238,896
-1.4%
0.00%0.0%
Q2 2020$2,930,000
+102.3%
242,193
+28.0%
0.00%
Q1 2020$1,448,000
-56.2%
189,283
+1.9%
0.00%
-100.0%
Q4 2019$3,308,000
+59.7%
185,769
+4.1%
0.00%
Q3 2019$2,072,000
+26.7%
178,521
+141.8%
0.00%
Q2 2019$1,635,000
+39.7%
73,830
+80.5%
0.00%
Q1 2019$1,170,000
+45.3%
40,900
+0.4%
0.00%
Q4 2018$805,000
+18.7%
40,728
+32.7%
0.00%
Q3 2018$678,00030,6940.00%
Other shareholders
KALVISTA PHARMACEUTICALS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 422,310$10,849,0005.86%
COMMODORE CAPITAL LP 214,467$5,510,0002.20%
Vivo Capital, LLC 1,863,296$47,868,0001.68%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 214,533$5,486,0001.45%
Nicholas Investment Partners, LP 594,130$15,263,0001.06%
Altium Capital Management LP 128,130$3,292,0000.91%
Affinity Asset Advisors, LLC 100,000$2,569,0000.87%
SILVERARC CAPITAL MANAGEMENT, LLC 50,000$1,285,0000.70%
APIS CAPITAL ADVISORS, LLC 30,000$771,0000.70%
Birchview Capital, LP 40,000$1,028,0000.61%
View complete list of KALVISTA PHARMACEUTICALS INC shareholders